Skip to content
Search

Latest Stories

Lake District pharmacy grapples with medicine shortages amidst growing crisis

Lake District pharmacy grapples with medicine shortages amidst growing crisis
79% of pharmacists fear for patient health according to Community Pharmacy England report

A Lake District pharmacy is grappling with significant medication supply issues, affecting its ability to provide essential drugs to customers amidst nationwide drug shortages.

According to Simon Butterworth, whose family has operated Collins & Butterworth Pharmacy in Hawkshead for nearly 40 years, voiced his concerns to the ITV stating that the staff is "having to spend time hunting for (medications), looking for it or doing our best to find ways to solve that problem" for distressed patients.


"They've got to know when they can get the medications they need," he added.

Butterworth also highlighted the financial strain pharmacies face due to the NHS's fixed tariff system.

"Certain items are actually costing more to buy than we get paid for them by the NHS. An item we were trying to get this morning was 250 per cent higher than the tariff price, which is significant and builds up over lots of items," he explained.

This situation reflects a broader crisis highlighted by a recent report from Community Pharmacy England (CPE), which found that 79 per cent of surveyed pharmacists believe "patient health is being put at risk due to medicine supply issues."

The National Pharmacy Agency (NPA) in a recent report highlighted that around ten pharmacies close each week, adding pressure on already overstretched GPs.

Moreover, Paul Rees, CEO of the NPA, condemned the commonplace nature of medicine shortages, calling it "totally unacceptable."

Pharmacists, he lamented, are left to navigate complex supply issues, often turning patients away due to stock unavailability.

CPE has warned that without intervention, these pressures could lead to even more closures.

Mubasher Ali, Chief Executive of Community Pharmacy Lancashire and South Cumbria told the ITV the urgency of addressing these funding issues:

"We need to make it more feasible for pharmacies. We've got to sort out this funding, it's absolutely crucial to us."

A Department of Health and Social Care (DHSC) spokesperson responded to these concerns, stating:

“There are around 14,000 licensed medicines and the overwhelming majority are in good supply. Supply issues can arise for a wide range of reasons and are not specific to the UK.

"Our priority is to mitigate risks posed by those issues and to help ensure that patients continue to get the treatments they need. Thankfully most issues can be managed with minimal impact to patients."

The spokesperson also emphasised the government's support for pharmacies:

“We recognise the vital role pharmacies play in our healthcare system and that’s why they are backed by £2.6 billion a year in government funding."

Despite this funding, the ongoing supply issues underscore a critical need for further action to ensure that pharmacies like Collins & Butterworth can continue to serve their communities effectively.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less